08:04 AM EDT, 06/21/2024 (MT Newswires) -- Ocugen ( OCGN ) said Friday that the Data and Safety Monitoring Board approved proceeding with the high dose of its experimental drug OCU410ST to treat Stargardt disease, a rare eye disease, in the dose-escalation phase of the study.

The company said that six patients with Stargardt disease have been dosed in the phase 1/2 trial in the low- and medium-dose cohorts to date, and an additional three patients will be dosed with the high dose in cohort 3.

The recommendation is based on data that established that a medium dose of the company's drug was safe and tolerable.